Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial

Published:2024-08 Issue: Volume: Page:
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Kim Paul,Sanchez Ana M,Penke Taylor J R,Tuson Hannah H,Kime James C,McKee Robert W,Slone William L,Conley Nicholas R,McMillan Lana J,Prybol Cameron J,Garofolo Paul M

Funder

U.S. Department of Health and Human Services

BARDA

Publisher

Elsevier BV

Reference24 articles.

1. Bacteriophage prehistory: is or is not Hankin, 1896, a phage reference?;Abedon;Bacteriophage,2011

2. Sur un microbe invisible antagoniste des bacilles dysentériques;D'Herelle;CR Acad Sci Paris,1917

3. Regulations of phage therapy across the world;Yang;Front Microbiol,2023

4. Bacteriophage therapy: clinical trials and regulatory hurdles;Furfaro;Front Cell Infect Microbiol,2018

5. Magistral phage preparations: is this the model for everyone?;Pirnay;Clin Infect Dis,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP